Affiliation:
1. School of Food and Biological Engineering, Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, Hefei University of Technology, Hefei, 230601, China
Abstract
Background:
Almost 50% of metastatic melanomas harbor BRAF mutations. Since 2011, BRAF
inhibitors have exhibited striking clinical benefits in BRAF-mutant melanoma patients. Unfortunately, their
therapeutic effects are often temporary. The resistance mechanisms vary and can be broadly classified as MAPK
reactivation-dependent and -independent. Elucidation of these resistance mechanisms provides new insights into
strategies for overcoming resistance. Indeed, several alternative treatment strategies, including changes in the
mode of administration, combinations of BRAF and MEK inhibitors, and immunotherapy have been verified as
beneficial to BRAF inhibitor-resistant melanoma patients.
Prospect:
In this review, we discuss promising strategies for overcoming drug resistance and highlighting the
prospects for discovering strategies to counteract BRAF inhibitor resistance.
Funder
Fundamental Research Funds for the Central Universities of China
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Pharmacology,Molecular Medicine
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献